Morgan Stanley raised the firm’s price target on BioNTech (BNTX) to $140 from $139 and keeps an Overweight rating on the shares. The firm ...

Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $139.00.

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

Below is Validea's guru fundamental report for BIONTECH SE - ADR (BNTX). Of the 22 guru strategies we follow, BNTX rates highest using our Value Investor model based on the published strategy of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

BioNTech SE (NASDAQ:BNTX) is a biotechnology company that develops and commercializes mRNA-based immunotherapies for cancer and infectious diseases. Its pipeline features vaccine and cancer ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against other best ...